Alternative For Patients With Limited Antibacterial Treatment Options
Orlynvah, a new drug for urinary tract infections, has been approved by the FDA, providing a new treatment option for patients with limited alternatives. The drug, a combination of sulopenem etzadroxil and probenecid, has shown effectiveness in treating uncomplicated UTIs in adult women. Clinical trials with over 3,800 participants demonstrated that Orlynvah works as well…